← Eichor
Condition: Tp53 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tp53

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Li-Fraumeni Syndrome/TP53 Biobank
Phase N/A · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04367246Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06413992Germline Genetic Testing of the TP53 Gene
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07419893A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refra
EARLY_Phase 1 · 1 location(s) · Children's National Research Institute · NCT07017816Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Nerviano Medical Sciences · NCT06549790Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNN
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06718153Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Phase 2 · 1 location(s) · Huazhong University of Science and Technology · NCT06005870Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp
Phase 3 · 215 location(s) · Kartos Therapeutics, Inc. · NCT06479135A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06908434A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07209449A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, R
Phase 1 · 5 location(s) · PMV Pharmaceuticals, Inc · NCT07372625Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With
Phase 3 · 242 location(s) · National Cancer Institute (NCI) · NCT07198074The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refra
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07240194Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Lamassu Bio Inc · NCT06578624Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT06517511ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · 4 location(s) · Newave Pharmaceutical Inc · NCT07342478Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-
Phase 1/Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07008638A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H
Phase 1 · 18 location(s) · AstraZeneca · NCT05877599Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06130579Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Phase 1 · 4 location(s) · Washington University School of Medicine · NCT06795009Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07499271JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Phase 1/Phase 2 · 15 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06386146Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chem
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06136351Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Phase N/A · 1 location(s) · Fudan University · NCT06369181ALPINE: Maintenance Letrozole/Abemaciclib
Phase 2 · 6 location(s) · Dana-Farber Cancer Institute · NCT06366347MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Phase N/A · 2 location(s) · Mohammad H. Abu Arja · NCT07242963NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
Phase N/A · 29 location(s) · AstraZeneca · NCT06494540Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Phase 3 · 1 location(s) · Qianfoshan Hospital · NCT06043973
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.